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Transcatheter  aortic  valve  embolisation  is  a rare  but  often  catastrophic
complication of  transcatheter  aortic  valve implantation (TAVI).  The incidence of
embolisation of the SAPIEN valve has declined over time with improved operator
experience,  use  of  CT  aortic  annular  measurements  to  guide  sizing,  accurate
identification  of  co-planar  valve  deployment  angles,  accurate  valve  prosthesis
positioning, and the availability of larger-sized prostheses. However, embolisation
still  occurs  with  an incidence of  0.5-0.8%. Most  embolisation,  as  in  this  case,
occurs into the ascending aorta or supra-annular location, but embolisation into
the left ventricular outflow tract and left ventricular cavity can also occur. In the
published literature,  aortic  embolisation is  managed by placing a second  TAVI
device and deploying the embolised valve in an aortic location. The embolised
valve leaflets remain fully open, essentially functioning as a “covered stent”.
As with  any  procedural  complications,  prevention is  often  better  than trying  to
solve the problem post hoc, so in this case I would start by suggesting that, when
there  was  extreme difficulty  in  advancing  the  delivery  system into  the  sheath
resulting in movement of the stent-valve frame on the delivery balloon, I would
have removed the system and re-prepared the entire delivery system or mounted
a new valve and delivery system.
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re-inflate the embolised valve frame fully. I would then remove the existing delivery
system, re-insert the sheath introducer/dilator and re-advance the sheath with its
introducer  through  the  embolised  valve  frame  to  facilitate  unobstructed
advancement of a second valve mounted on a new delivery system.
I would then go ahead and perform a standard TAVI implant under rapid RV pacing
control with a new 26 mm SAPIEN 3 transcatheter valve delivery system.
Based on the fact that this patient has significant atherothrombotic material in the
aortic arch, I would suggest leaving the embolised valve in the ascending aorta
and  not  trying  to  snare  the  device  and pull  it  across  the  aortic  arch.  I  would
withdraw  the  sheath  until  the  embolised  valve  was  fully  uncovered.  Using
preprocedural CT dimensions, I would take an oversized balloon approximating
the ascending aortic dimensions and post-dilate the embolised valve frame into
position in the ascending aorta.
An alternative strategy would be to deploy a second 26 mm SAPIEN 3 valve in the
correct  location  and  then  place  the  patient  on  femoro-femoral  arteriovenous
circulatory bypass and open the ascending aorta to remove the embolised valve
directly.  However,  given  the  patient’s  atherosclerotic  aortic  disease,  I  feel  this
would carry a substantial risk of stroke and perioperative morbidity.
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